We're taking a closer look at ProKidney today, as tone of the only stocks in the green during today's session: its shares moved 4.8% compared to -2.2% for the S&P 500. Increased investor interest and volatility surrounding the stock are not reason enough to buy in -- you should first perform your own due diligence. Here are some figures that can get you started:
ProKidney Corp., a clinical-stage biotechnology company, engages in developing cellular therapy cures for cancer.
ProKidney has moved -9.3% over the last year compared to -15.7% for the S&P 500 -- a difference of 6.3%
The company has a Price to Book (P/B) ratio of 300 in contrast to the S&P 500's average ratio of 2.95
ProKidney is part of the Healthcare sector, which has an average P/E ratio of 13.21 and an average P/B of 4.07
At Market Interference, our goal is to help educate investors about headline-making stocks. We believe informed investment decisions are good investment decisions. subscribe to our free newsletter to stay on top of each day's market movements!